Long-term efficacy of tafamidis in patients with transthyretin amyloid cardiomyopathy by National Amyloidosis Centre stage.

Eur J Heart Fail · 2025 · PMC12803551 · PMID 40488446

Europe PMC DOI

hedged sentence

0.2980

closest p · 6.0× alpha

0.2980

boldest claim

The sentences

a numerical trendp = 0.298not close (p > 0.1)

74%; HR 0.51, p = 0.003); with a numerical trend at stage III (69% vs. 88%; HR 0.75, p = 0.298).

also in 1,012 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.